tranexamic acid has been researched along with Arthritis, Rheumatoid in 15 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Arthritis, Rheumatoid: A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.
Excerpt | Relevance | Reference |
---|---|---|
"We aimed to determine the efficacy and safety of multiple doses of intravenous tranexamic acid (IV-TXA) on perioperative blood loss in patients with rheumatoid arthritis (RA) who had undergone primary unilateral total knee arthroplasty (TKA)." | 9.41 | Multiple intravenous tranexamic acid doses in total knee arthroplasty in patients with rheumatoid arthritis: a randomized controlled study. ( Gao, CX; Gao, XJ; Kang, BX; Ma, YH; Sun, ST; Xiao, LB; Xie, J; Xu, H; Xu, XR; Zhai, WT; Zhang, J; Zhao, C; Zhong, S, 2021) |
"This clinical trial is designed to evaluate the effect of multiple-dose tranexamic acid (TXA) on perioperative blood loss in patients with rheumatoid arthritis (RA)." | 9.34 | Multiple-dose tranexamic acid for perioperative blood loss in total knee arthroplasty in patients with rheumatoid arthritis:a single-blinded, randomised, parallel-controlled study protocol in China. ( Gao, CX; Kang, BX; Ma, YH; Sun, ST; Xiao, LB; Xie, J; Xu, H; Zhai, WT; Zhang, J; Zhong, S, 2020) |
"In a double-blind controlled study on 45 rheumatoid arthritis patients, no effect of tranexamic acid (Cyklocapron, 4." | 9.05 | Lack of effect of tranexamic acid on rheumatoid arthritis. ( Arfelt, E; Brandslund, I; Hindersson, P; Jensen, A; Lund, HI; Nielsen, EF; Rasmussen, GG; Siersted, HC; Teisner, B; Urfe, P, 1984) |
"We aimed to determine the efficacy and safety of multiple doses of intravenous tranexamic acid (IV-TXA) on perioperative blood loss in patients with rheumatoid arthritis (RA) who had undergone primary unilateral total knee arthroplasty (TKA)." | 5.41 | Multiple intravenous tranexamic acid doses in total knee arthroplasty in patients with rheumatoid arthritis: a randomized controlled study. ( Gao, CX; Gao, XJ; Kang, BX; Ma, YH; Sun, ST; Xiao, LB; Xie, J; Xu, H; Xu, XR; Zhai, WT; Zhang, J; Zhao, C; Zhong, S, 2021) |
"This clinical trial is designed to evaluate the effect of multiple-dose tranexamic acid (TXA) on perioperative blood loss in patients with rheumatoid arthritis (RA)." | 5.34 | Multiple-dose tranexamic acid for perioperative blood loss in total knee arthroplasty in patients with rheumatoid arthritis:a single-blinded, randomised, parallel-controlled study protocol in China. ( Gao, CX; Kang, BX; Ma, YH; Sun, ST; Xiao, LB; Xie, J; Xu, H; Zhai, WT; Zhang, J; Zhong, S, 2020) |
"In a double-blind controlled study on 45 rheumatoid arthritis patients, no effect of tranexamic acid (Cyklocapron, 4." | 5.05 | Lack of effect of tranexamic acid on rheumatoid arthritis. ( Arfelt, E; Brandslund, I; Hindersson, P; Jensen, A; Lund, HI; Nielsen, EF; Rasmussen, GG; Siersted, HC; Teisner, B; Urfe, P, 1984) |
"Only one patient in IV group exhibited deep venous thrombosis." | 2.87 | Tranexamic acid in primary total knee arthroplasty without tourniquet: a randomized, controlled trial of oral versus intravenous versus topical administration. ( Cao, C; Li, DH; Li, LL; Meng, WK; Pei, FX; Wang, D; Wang, HY; Zeng, WN; Zhou, ZK, 2018) |
" In Group A, 1 g of tranexamic acid dissolved in 250 ml of normal saline was intravenously infused before deflation of the tourniquet; another intravenous administration of the same drug of the same dosage was given 3 hours later." | 2.73 | [Clinical comparative studies on effect of tranexamic acid on blood loss associated with total knee arthroplasty]. ( Gao, Z; Yu, J; Zhang, F, 2007) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (6.67) | 18.7374 |
1990's | 1 (6.67) | 18.2507 |
2000's | 2 (13.33) | 29.6817 |
2010's | 2 (13.33) | 24.3611 |
2020's | 9 (60.00) | 2.80 |
Authors | Studies |
---|---|
Li, J | 2 |
Li, Y | 1 |
Huang, Y | 1 |
Zhang, H | 1 |
Ye, P | 1 |
Deng, P | 1 |
Chen, J | 1 |
Qi, X | 1 |
Zeng, J | 1 |
Feng, W | 2 |
Zeng, Y | 1 |
Cao, G | 1 |
Zhang, S | 1 |
Wang, Y | 1 |
Xu, H | 3 |
Quan, S | 1 |
Cai, L | 1 |
Yao, J | 1 |
Tan, H | 1 |
Pei, F | 2 |
Ghaffari, S | 1 |
Fateh, S | 1 |
Faramarzi, F | 1 |
Rafiei, A | 1 |
Razavipour, M | 1 |
Zafari, P | 1 |
Morse, KW | 2 |
Heinz, NK | 2 |
Abolade, JM | 2 |
Wright-Chisem, JI | 2 |
Russell, LA | 2 |
Zhang, M | 2 |
Mirza, SZ | 2 |
Orange, DE | 2 |
Figgie, MP | 2 |
Sculco, PK | 2 |
Goodman, SM | 2 |
Lei, Y | 1 |
Liu, J | 1 |
Liang, X | 1 |
Hu, N | 1 |
Huang, W | 1 |
Kang, BX | 2 |
Gao, CX | 2 |
Zhong, S | 2 |
Zhang, J | 2 |
Xie, J | 2 |
Sun, ST | 2 |
Ma, YH | 2 |
Zhai, WT | 2 |
Xiao, LB | 2 |
Li, S | 1 |
Lu, Q | 1 |
Ma, H | 1 |
Liu, P | 1 |
Xu, XR | 1 |
Zhao, C | 1 |
Gao, XJ | 1 |
Wang, D | 1 |
Wang, HY | 1 |
Cao, C | 1 |
Li, LL | 1 |
Meng, WK | 1 |
Pei, FX | 1 |
Li, DH | 1 |
Zhou, ZK | 1 |
Zeng, WN | 1 |
Sepah, YJ | 1 |
Umer, M | 1 |
Ahmad, T | 1 |
Nasim, F | 1 |
Chaudhry, MU | 1 |
Umar, M | 1 |
Zhang, F | 1 |
Gao, Z | 1 |
Yu, J | 1 |
Rasmussen, GG | 1 |
Brandslund, I | 1 |
Urfe, P | 1 |
Teisner, B | 1 |
Siersted, HC | 1 |
Hindersson, P | 1 |
Lund, HI | 1 |
Nielsen, EF | 1 |
Arfelt, E | 1 |
Jensen, A | 1 |
Ronday, HK | 1 |
Te Koppele, JM | 1 |
Greenwald, RA | 1 |
Moak, SA | 1 |
De Roos, JA | 1 |
Dijkmans, BA | 1 |
Breedveld, FC | 1 |
Verheijen, JH | 1 |
Tanaka, N | 1 |
Sakahashi, H | 1 |
Sato, E | 1 |
Hirose, K | 1 |
Ishima, T | 1 |
Ishii, S | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Comparative Study of the Efficiency of Oral Tranexamic Tcid vs. Oral Tminocaproic Acid to Reduce Blood Loss and Transfusion After Total Knee Replacement. A Prospective, Randomized, Double Blinded Controlled Clinical Trial.[NCT03365999] | Phase 2 | 92 participants (Actual) | Interventional | 2017-10-15 | Completed | ||
Intravenous Tranexamic Acid to Reduce Blood Loss in Reverse Total Shoulder Arthroplasty[NCT02043132] | Phase 2/Phase 3 | 116 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
Comparison of Combined Topical Tranexamic Acid With Floseal® With Intravenous Tranexamic Acid on Blood Loss in Total Knee Arthroplasty[NCT03328832] | Phase 4 | 70 participants (Actual) | Interventional | 2017-09-12 | Completed | ||
Evaluating the Use of Tranexamic Acid (TXA) in Total Joint Arthroplasty[NCT03825939] | Phase 4 | 52 participants (Actual) | Interventional | 2015-04-21 | Terminated (stopped due to Lack of patient enrollment due to only one surgeon that was enrolling.) | ||
Randomized Placebo Controlled Study Using Tranexamic Acid in Revision Total Hip Arthroplasty[NCT00375440] | 0 participants (Actual) | Interventional | 2005-02-28 | Withdrawn (stopped due to Study halted prematurely as investigator left the institution.) | |||
The Blood Saving Effect and Wound-related Complications of Tranexamic Acid in Mininally Invasive Total Knee Arthroplasty With Rivaroxaban as Thromboprophylaxis[NCT02458729] | Phase 4 | 294 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
Blood-saving Effect of Kaolin-based Hemostatic Gauze Combined With Intravenous Tranexamic Acid in Total Knee Arthroplasty[NCT05504577] | Phase 4 | 120 participants (Anticipated) | Interventional | 2022-03-16 | Recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Deep venous thrombosis" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 0 |
Normal Saline | 0 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Hematoma" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 0 |
Normal Saline | 0 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Infection" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 0 |
Normal Saline | 0 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Myocardial infarction" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 0 |
Normal Saline | 1 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Pulmonary Embolism" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 0 |
Normal Saline | 0 |
Total Blood Loss as calculated according to method as described by Good et al. Total Blood Loss (mL) = 1000 X Hb(loss)/Hb(initial) (NCT02043132)
Timeframe: Preoperative through Postoperative Days 1 and 2
Intervention | Total Blood Loss (mL) (Mean) |
---|---|
Tranexamic Acid | 1122.4 |
Normal Saline | 1472 |
Total Drain Output as measured postoperatively 0-48 hours (NCT02043132)
Timeframe: 0-48 hours postoperatively
Intervention | mL (Mean) |
---|---|
Tranexamic Acid | 221 |
Normal Saline | 372 |
Total hemoglobin loss estimated using the formula for total blood volume described by Nadler et al Hb(loss) = blood volume (L) x [Hb(initial)(g/L) - Hb(final)(g/L)] + Hb(transfused) (NCT02043132)
Timeframe: Preoperative through Postoperative Days 1 and 2
Intervention | g (Mean) |
---|---|
Tranexamic Acid | 154.6 |
Normal Saline | 200.1 |
We will record the event of blood transfusion, and calculate the incidence of transfusion (NCT03328832)
Timeframe: From the operation to the postoperative day 3 or 4
Intervention | Participants (Count of Participants) |
---|---|
Combined Topical TXA and Floseal | 1 |
Topical TXA Alone | 0 |
The composite of any venous thromoembolism events, ischemic heart attacks, cerebrovascular accidents (NCT03328832)
Timeframe: within 30 days of the operation
Intervention | Participants (Count of Participants) |
---|---|
Combined Topical TXA and Floseal | 0 |
Topical TXA Alone | 0 |
Total blood loss was calculated according to Nadler et al., which used maximum postoperative reduction of the Hb level adjust for weight and height of the patient. The formula is as follows, Total blood loss = (Total blood volume x [change in Hb level / preoperative Hb level])x1000+volume transfused (NCT03328832)
Timeframe: From the operation to the postoperative day 3 or 4
Intervention | ml (Mean) |
---|---|
Combined Topical TXA and Floseal | 678 |
Topical TXA Alone | 733 |
Measured in Days (NCT03825939)
Timeframe: At Hospital Discharge
Intervention | Days (Mean) |
---|---|
Intravenous Tranexamic Acid | 3 |
Intravenous Placebo | 3 |
Intravenous Tranexamic Acid Followed by Intravenous Placebo | 3 |
7 trials available for tranexamic acid and Arthritis, Rheumatoid
Article | Year |
---|---|
Effectiveness of preemptive antifibrinolysis with tranexamic acid in rheumatoid arthritis patients undergoing total knee arthroplasty: a study protocol for a randomized controlled trial.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthritis, Rheumatoid; Arthroplasty, Replaceme | 2020 |
Multiple-dose tranexamic acid for perioperative blood loss in total knee arthroplasty in patients with rheumatoid arthritis:a single-blinded, randomised, parallel-controlled study protocol in China.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthritis, Rheumatoid; Arthroplasty, Rep | 2020 |
Multiple intravenous tranexamic acid doses in total knee arthroplasty in patients with rheumatoid arthritis: a randomized controlled study.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthritis, Rheumatoid; Arthroplasty, Rep | 2021 |
Tranexamic acid in primary total knee arthroplasty without tourniquet: a randomized, controlled trial of oral versus intravenous versus topical administration.
Topics: Administration, Intravenous; Administration, Oral; Aged; Antifibrinolytic Agents; Arthritis, Rheumat | 2018 |
[Clinical comparative studies on effect of tranexamic acid on blood loss associated with total knee arthroplasty].
Topics: Aged; Antifibrinolytic Agents; Arthritis; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Bl | 2007 |
Lack of effect of tranexamic acid on rheumatoid arthritis.
Topics: Adult; Antigen-Antibody Complex; Arthritis, Rheumatoid; Clinical Trials as Topic; Complement Activat | 1984 |
Tranexamic acid, an inhibitor of plasminogen activation, reduces urinary collagen cross-link excretion in both experimental and rheumatoid arthritis.
Topics: Amino Acids; Animals; Antifibrinolytic Agents; Arthritis; Arthritis, Rheumatoid; Biomarkers; Collage | 1998 |
8 other studies available for tranexamic acid and Arthritis, Rheumatoid
Article | Year |
---|---|
Predictors and complications of blood transfusion in rheumatoid arthritis patients undergoing total joint arthroplasty.
Topics: Antifibrinolytic Agents; Arthritis, Rheumatoid; Arthroplasty, Replacement, Hip; Blood Loss, Surgical | 2023 |
The efficacy and safety of tranexamic acid in rheumatoid arthritis patients undergoing simultaneous bilateral total knee arthroplasty: a multicenter retrospective study.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthritis, Rheumatoid; Arthroplasty, Replaceme | 2023 |
The effect of tranexamic acid on synovium of patients undergoing arthroplasty and anterior cruciate ligament reconstruction surgery.
Topics: Adult; Anterior Cruciate Ligament Reconstruction; Arthritis, Rheumatoid; Arthroplasty; Cells, Cultur | 2023 |
Tranexamic Acid Does Not Reduce the Risk of Transfusion in Rheumatoid Arthritis Patients Undergoing Total Joint Arthroplasty.
Topics: Antifibrinolytic Agents; Arthritis, Rheumatoid; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 2020 |
Letter to the Editor on "Tranexamic Acid Does Not Reduce the Risk of Transfusion in Rheumatoid Arthritis Patients Undergoing Total Joint Arthroplasty".
Topics: Antifibrinolytic Agents; Arthritis, Rheumatoid; Arthroplasty; Blood Transfusion; Humans; Tranexamic | 2020 |
Response to Letter to the Editor on: Tranexamic Acid Does Not Reduce the Risk of Transfusion in Rheumatoid Arthritis Patients Undergoing Total Joint Arthroplasty.
Topics: Antifibrinolytic Agents; Arthritis, Rheumatoid; Arthroplasty; Blood Transfusion; Humans; Tranexamic | 2020 |
Use of tranexamic acid is a cost effective method in preventing blood loss during and after total knee replacement.
Topics: Antifibrinolytic Agents; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgica | 2011 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |
Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Drug Administrat | 2001 |